Table 3.
Cardiovascular outcomes of SGLT2 inhibitors trials.
| EMPA-REG | CANVAS | CREDENCE | DECLARE-TIMI 58 | DAPA–HF | VERTIS-CV | |
|---|---|---|---|---|---|---|
| References | (74) | (60) | (77) | (69) | (66) | (78) |
| Drugs | Empaglifozin | Canagliflozin | Canagliflozin | Dapagliflozin | Dapagliflozin | Ertugliflozin |
| Study population | T2DM patients with CVD | T2DM patients with CVD or CV risk factors | T2DM patients with CKD | T2DM patients with ASCVD or CV risk factors | Patients with rHF | T2DM patients with ASCVD |
| Number of patients | 7,020 | 10,142 | 4,401 | 17,150 | 4,744 | 8,246 |
| Median follow-up | 3.1 years | 2.4 years | 2.6 years | 4.2 years | 18.2 months | 3.5 years |
| CV outcomes | ||||||
| MACE | 0.86 (0.74–0.99) | 0.86 (0.75–0.97) | 0.80 (0.67–0.95) | 0.93 (0.84–1.03) | – | 0.97 (0.85–1.11) |
| CV death | 0.62 (0.49–0.77) | 0.87 (0.72–1.06) | – | 0.98 (0.82–1.17) | 0.82 (0.69–0.98) | 0.92 (0.77–1.11) |
| CV death or HHF | 0.66 (0.55–0.79) | – | – | 0.83 (0.73–0.95) | 0.75 (0.65–0.85) | – |
ASCVD, atherosclerotic cardiovascular diseases; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular diseases; HF, heart failure; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular events: including death from cardiovascular causes, non-fatal MI, and non-fatal stroke; T2DM, type 2 diabetes mellitus.